Selectivity sets off $37M series A for mTOR company Aeovian
Selectivity data for Aeovian’s mTORC1 inhibitor attracted venBio, Sofinnova Investments to lead series A
Preclinical selectivity data for Aeovian’s mTORC1 inhibitor prompted venBio and Sofinnova Investments to co-lead the biotech’s $37 million series A after long eyeing the space.
“mTORC1 selective inhibition has been a Holy Grail target in big pharma for a long time,” venBio’s Richard Gaster told BioCentury. The master